Congress commits to global TB control—but leaves domestic cases behind
H.R. 10223 — End Tuberculosis Now Act of 2026 · Filed by Ami Bera (D-CA) · 9 cosponsors · Introduced Sep 2, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Foreign Assistance Act to establish a comprehensive U.S. global tuberculosis prevention and treatment program through 2032. It authorizes the President to provide foreign aid for TB diagnosis, treatment, and prevention in high-burden countries, with specific goals to reduce TB incidence by 80% and mortality by 90% by 2030, treat 30 million people with TB preventive therapy, and achieve 90% diagnosis and treatment rates. The bill requires annual reporting on program outcomes and mandates coordination across federal agencies and with international partners.
Why we flagged it
The bill's operative mechanism is a straightforward authorization of foreign assistance for tuberculosis control. It establishes policy objectives, measurable goals, and reporting requirements for U.S. TB programs abroad. This is standard foreign aid legislation with public health framing.
What the text implies
- Sunset clause (Jan 1, 2033) means program authority expires unless Congress reauthorizes; no permanent commitment despite ambitious 2030 goals.
- Bill authorizes but does not appropriate funds; actual spending depends on separate appropriations votes, creating implementation uncertainty.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (TB drug and vaccine development); diagnostic device manufacturers (molecular diagnostics, point-of-care tests); international NGOs and implementing partners (program delivery contracts)